U. at Buffalo participates in trial of drug derived from bat saliva

02/24/2010 | American City Business Journals

The University at Buffalo's Department of Neurology and the Jacobs Neurological Institute received approval to enroll patients in a clinical trial of desmosteplase, a drug candidate for acute ischemic stroke that was derived from a bioengineered protein in vampire bats' saliva. The study is part of a worldwide trial spearheaded by Lundbeck.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX